Adam Mor is a Rheumatology/Immunology physician affiliated with Columbia University Irving Medical Center. OpenAlex indexes 57 publications with 1,392 citations (h-index 20).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
161 Fort Washington Ave Fl 2
New York, NY 10032
Telephone
212-305-4308Registry record last updated 21 Jun 2018.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ROCHE MOLECULAR SYSTEMS, INC.Program year20258 payments
- GlaxoSmithKline, LLC.Program year20251 payment
- GlaxoSmithKline, LLC.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
67.2%Corticosteroid67.2%Prednisone100%Part D≥12 patientsCancer & immunology
32.8%TNF inhibitor32.8%Humira(Cf) Pen100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
5 NIH research awards on record, funded 2016–2026 per NIH RePORTER. The latest:
- A systematic approach to uncover the basic mechanisms of checkpoint inhibitor immune related adverse events
Columbia University Health Sciences
FY2026$737,672R01AI175498 - The role of tissue-resident T cells in osteoarthritis during the transition to inflammatory arthritis induced by immune checkpoint inhibitors
Columbia University Health Sciences
FY2026$452,375R21AI197040 - Novel mechanisms regulating PD-1 signaling and function
Columbia University Health Sciences
FY2026$434,023R01AI125640
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Understanding the Inflammatory Aspect of Osteoarthritis: Lessons from Immune Checkpoint Inhibitors
Journal of Clinical Medicine
2026 - Osteoarthritis increases the risk of inflammatory arthritis due to immune checkpoint inhibitors associated with tissue-resident memory T cells
Journal for ImmunoTherapy of Cancer
2025 - PD-1 signaling uncovers a pathogenic subset of T cells in inflammatory arthritis
Arthritis Research & Therapy
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Stanley Fahn, MD
Columbia University Irving Medical Center
Rebecca Hahn, MD
Columbia University Irving Medical Center
Susheel Kodali, MD
Columbia University Irving Medical Center
Ronald Wapner, MD
Columbia University Irving Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”